Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types

PURPOSE: Berzosertib (formerly M6620) is the first-in-class inhibitor of ataxia–telangiectasia and Rad3-related protein, a key component of the DNA damage response, and being developed in combination with chemotherapy for the treatment of patients with advanced cancers. The objectives of this analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Terranova, Nadia, Jansen, Mendel, Falk, Martin, Hendriks, Bart S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870753/
https://www.ncbi.nlm.nih.gov/pubmed/33145616
http://dx.doi.org/10.1007/s00280-020-04184-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870753/
https://www.ncbi.nlm.nih.gov/pubmed/33145616
http://dx.doi.org/10.1007/s00280-020-04184-z

Ejemplares similares